Antibiotic drug Nitrofurantoin (AMCo, Morningside Healthcare, Morningside Pharmaceuticals and Alliance Healthcare) (50507)
Antibiotic drug Nitrofurantoin (AMCo, Morningside Healthcare, Morningside Pharmaceuticals and Alliance Healthcare) (50507)

The following Competition practice note provides comprehensive and up to date legal information covering:

  • Antibiotic drug Nitrofurantoin (AMCo, Morningside Healthcare, Morningside Pharmaceuticals and Alliance Healthcare) (50507)
  • Case facts
  • Timeline
  • Commentary
  • Related cases

CASE HUB

See further, timeline ,commentary and related cases.

Case facts

OutlineCMA Article 101 TFEU/Chapter I investigation into AMCo (now Advanz Pharma Services (UK) Limited), Morningside Healthcare Limited, Morningside Pharmaceuticals Limited and Alliance Healthcare (Distribution) Limited in relation to an alleged breach of competition law concerning the supply of the antibiotic drug Nitrofurantoin.

Latest developmentsOn 25 July 2019, the CMA issued a statement of objections to AMCo (now Advanz Pharma Services (UK) Limited), Morningside Healthcare Limited, Morningside Pharmaceuticals Limited and Alliance Healthcare (Distribution) Limited.

Parties• Advanz Pharma Services (UK) Limited (Advanz): Advanz is a wholly-owned subsidiary of Mercury Pharma Group Limited, which is incorporated in the UK. It is principally engaged in the provision of support services on behalf of the group headed by Concordia International Corp. (formerly Concordia Healthcare Corp).

• Mercury Pharma Group Limited (Mercury): Mercury is a wholly-owned subsidiary of Concordia Holdings (UK) Limited and is an intermediate holding company. The principal activity of Mercury is that of a holding company of the operating and group services businesses and providing licensing of product rights.

• Cinven Capital Management (CCM): The principal activity of CCM is to act as an intermediate holding company. CCM’s ultimate parent entity is Cinven Partners LLP.

• Ge

Popular documents